Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista de Saúde Pública |
Texto Completo: | https://www.revistas.usp.br/rsp/article/view/152004 |
Resumo: | OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in BRCA1/2 genes and of preventative strategies for the relatives of patients diagnosed with ovarian cancer associated with this mutation. METHODS: The study analyzed the cost effectiveness by developing an analysis of the Markov decision process from the perspective of the National Health System. The strategies compared reflect upon the adoption of genetic testing and preventative strategies for relatives or the usual care currently proposed. The incremental cost-effectiveness ratio was expressed in terms of cost per case avoided. The sensitivity analysis was performed in a univariate and deterministic manner. RESULTS: The study showed increments for effectiveness and for costs when performing genetic testing and adopting prophylactic measures for family members. The incremental cost-effectiveness ratio was estimated at R$908.58 per case of cancer avoided, a figure considered lower than the study’s cost-effectiveness threshold (R$7,543.50). CONCLUSIONS: The program analyzed should be considered a cost-effective strategy for the national situation. Studies in various other countries have reached similar conclusions. One possible ramification of this research might the need to perform a budgetary-impact analysis of making the program one of the country’s health policies |
id |
USP-23_a4da92e5f5c31dee51304de32b1bf6e3 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/152004 |
network_acronym_str |
USP-23 |
network_name_str |
Revista de Saúde Pública |
repository_id_str |
|
spelling |
Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutationOvarian Neoplasms, diagnosisGenes, BRCA1Genes, BRCA2Early Detection of Cancer, economicsCost-Effectiveness EvaluationOBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in BRCA1/2 genes and of preventative strategies for the relatives of patients diagnosed with ovarian cancer associated with this mutation. METHODS: The study analyzed the cost effectiveness by developing an analysis of the Markov decision process from the perspective of the National Health System. The strategies compared reflect upon the adoption of genetic testing and preventative strategies for relatives or the usual care currently proposed. The incremental cost-effectiveness ratio was expressed in terms of cost per case avoided. The sensitivity analysis was performed in a univariate and deterministic manner. RESULTS: The study showed increments for effectiveness and for costs when performing genetic testing and adopting prophylactic measures for family members. The incremental cost-effectiveness ratio was estimated at R$908.58 per case of cancer avoided, a figure considered lower than the study’s cost-effectiveness threshold (R$7,543.50). CONCLUSIONS: The program analyzed should be considered a cost-effective strategy for the national situation. Studies in various other countries have reached similar conclusions. One possible ramification of this research might the need to perform a budgetary-impact analysis of making the program one of the country’s health policiesUniversidade de São Paulo. Faculdade de Saúde Pública2018-11-22info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/xmlhttps://www.revistas.usp.br/rsp/article/view/15200410.11606/S1518-8787.2018052000643Revista de Saúde Pública; Vol. 52 (2018); 94Revista de Saúde Pública; Vol. 52 (2018); 94Revista de Saúde Pública; v. 52 (2018); 941518-87870034-8910reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/rsp/article/view/152004/148786https://www.revistas.usp.br/rsp/article/view/152004/148787Copyright (c) 2018 Revista de Saúde Públicainfo:eu-repo/semantics/openAccessRamos, Marcelo Cristiano de AzevedoFolgueira, Maria Aparecida Azevedo KoikeMaistro, SimoneCampolina, Alessandro GonçalvesSoárez, Patricia Coelho deBock, Geertruida Hendrika deNovaes, Hillegonda Maria DutilhDiz, Maria Del Pilar Estevez2019-04-04T10:07:00Zoai:revistas.usp.br:article/152004Revistahttps://www.revistas.usp.br/rsp/indexONGhttps://www.revistas.usp.br/rsp/oairevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2019-04-04T10:07Revista de Saúde Pública - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation |
title |
Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation |
spellingShingle |
Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation Ramos, Marcelo Cristiano de Azevedo Ovarian Neoplasms, diagnosis Genes, BRCA1 Genes, BRCA2 Early Detection of Cancer, economics Cost-Effectiveness Evaluation |
title_short |
Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation |
title_full |
Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation |
title_fullStr |
Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation |
title_full_unstemmed |
Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation |
title_sort |
Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation |
author |
Ramos, Marcelo Cristiano de Azevedo |
author_facet |
Ramos, Marcelo Cristiano de Azevedo Folgueira, Maria Aparecida Azevedo Koike Maistro, Simone Campolina, Alessandro Gonçalves Soárez, Patricia Coelho de Bock, Geertruida Hendrika de Novaes, Hillegonda Maria Dutilh Diz, Maria Del Pilar Estevez |
author_role |
author |
author2 |
Folgueira, Maria Aparecida Azevedo Koike Maistro, Simone Campolina, Alessandro Gonçalves Soárez, Patricia Coelho de Bock, Geertruida Hendrika de Novaes, Hillegonda Maria Dutilh Diz, Maria Del Pilar Estevez |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Ramos, Marcelo Cristiano de Azevedo Folgueira, Maria Aparecida Azevedo Koike Maistro, Simone Campolina, Alessandro Gonçalves Soárez, Patricia Coelho de Bock, Geertruida Hendrika de Novaes, Hillegonda Maria Dutilh Diz, Maria Del Pilar Estevez |
dc.subject.por.fl_str_mv |
Ovarian Neoplasms, diagnosis Genes, BRCA1 Genes, BRCA2 Early Detection of Cancer, economics Cost-Effectiveness Evaluation |
topic |
Ovarian Neoplasms, diagnosis Genes, BRCA1 Genes, BRCA2 Early Detection of Cancer, economics Cost-Effectiveness Evaluation |
description |
OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in BRCA1/2 genes and of preventative strategies for the relatives of patients diagnosed with ovarian cancer associated with this mutation. METHODS: The study analyzed the cost effectiveness by developing an analysis of the Markov decision process from the perspective of the National Health System. The strategies compared reflect upon the adoption of genetic testing and preventative strategies for relatives or the usual care currently proposed. The incremental cost-effectiveness ratio was expressed in terms of cost per case avoided. The sensitivity analysis was performed in a univariate and deterministic manner. RESULTS: The study showed increments for effectiveness and for costs when performing genetic testing and adopting prophylactic measures for family members. The incremental cost-effectiveness ratio was estimated at R$908.58 per case of cancer avoided, a figure considered lower than the study’s cost-effectiveness threshold (R$7,543.50). CONCLUSIONS: The program analyzed should be considered a cost-effective strategy for the national situation. Studies in various other countries have reached similar conclusions. One possible ramification of this research might the need to perform a budgetary-impact analysis of making the program one of the country’s health policies |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-11-22 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/rsp/article/view/152004 10.11606/S1518-8787.2018052000643 |
url |
https://www.revistas.usp.br/rsp/article/view/152004 |
identifier_str_mv |
10.11606/S1518-8787.2018052000643 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/rsp/article/view/152004/148786 https://www.revistas.usp.br/rsp/article/view/152004/148787 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Revista de Saúde Pública info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Revista de Saúde Pública |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/xml |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Saúde Pública |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Saúde Pública |
dc.source.none.fl_str_mv |
Revista de Saúde Pública; Vol. 52 (2018); 94 Revista de Saúde Pública; Vol. 52 (2018); 94 Revista de Saúde Pública; v. 52 (2018); 94 1518-8787 0034-8910 reponame:Revista de Saúde Pública instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Revista de Saúde Pública |
collection |
Revista de Saúde Pública |
repository.name.fl_str_mv |
Revista de Saúde Pública - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
revsp@org.usp.br||revsp1@usp.br |
_version_ |
1800221799928037376 |